Other pathways include pathways in cancer (IL6 and AKT1), non-alcoholic fatty liver disease (AKT1 and IL1B), and the CAMP signaling pathway (AKT1). This evidence concerns the gene CAMP and metabolic dysfunction-associated steatotic liver disease.